Entering text into the input field will update the search result below

ABIO ARCA biopharma, Inc.
Stock Price & Overview

$2.02-0.005 (-0.25%)3:59 PM 09/26/23
NASDAQ | $USD | Post-Market: $2.01 -0.01 (-0.25%) 4:00 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Company Profile

ARCA biopharma, Inc. logo
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.
  • 10170 Church Ranch Way
  • Suite 100
  • Westminster, CO, 80021
  • United States
Phone Number
720 940 2200
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.